Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer

Fig. 1

The combination of cisplatin and SW IV-134 shows enhanced reduction in ovarian cancer cell viability. A, SKOV-3, B, OVCAR-3 and C, ID8 cells were treated with cisplatin (5μg/ml), SW IV-134 (varying concentrations), or the combination of the two drugs using the same concentrations. Titer-Glo viability assays were performed after 72 h (SKOV-3 and OVCAR-3) or 36 h (ID8) of treatment. The data were normalized to DMSO treated control cells. (***p < 0.001) (n = 3)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us